IRVINE, Calif., Aug. 27, 2026 /PRNewswire/ — Aspen Medical Products (Aspen), the industry leader in spine solutions for pain and mobility management, today announced an important enhancement to its executive leadership structure designed to support the company’s continued growth and long-term strategic objectives.
Aspen Medical Products Strengthens Executive Leadership Team with Appointment of Steve Paul as President
2 min read Premium comments
leadershipCEOpresidentappointmentAspen Medical ProductsJim CloarSteve Paulexecutive
Effective immediately, Aspen has separated the combined chief executive officer and president position into two distinct executive roles. Jim Cloar will continue to serve as CEO, while Steve Paul has joined the company as president.
The leadership evolution strengthens Aspen’s executive team and positions the company for its next phase of growth. As CEO, Cloar will increase his focus on strategic initiatives, mergers and acquisitions, innovation and long-term expansion opportunities, while Paul will assume responsibility for many of the company’s day-to-day operations, partnering closely with Cloar to continue Aspen’s strong operational and commercial performance.
“Steve Paul brings demonstrated commercial success in the orthotic market along with his success in various medical device enterprises,” said Jim Cloar, chief executive officer. “I am excited to work closely with Steve as we together lead Aspen’s future, expand our strong growth across all market segments and accelerate our focus on innovation and collaboration with partners for mutual success. Steve will be an amazing partner to me as we continue to grow our industry-leading organization.”
Paul brings more than three decades of executive leadership experience across healthcare solutions, medical devices and orthopedic bracing. Throughout his career, he has held senior leadership positions with industry-leading organizations including Breg, Vertos Medical, Masimo and Boston Scientific, where he successfully led commercial growth initiatives and developed hybrid distribution strategies to drive revenue expansion and organizational alignment. His collaborative leadership style and deep understanding of the orthopedic marketplace make him exceptionally well positioned to help lead Aspen’s continued success.
“I am honored to step into this new role at such an exciting time for Aspen Medical Products,” said Steve Paul, president. “I look forward to working with Jim and the entire Aspen team to accelerate our strategic goals, continue delivering innovative solutions and create even greater value for our customers, business partners and employees.”
The executive leadership transition reflects Aspen’s ongoing commitment to investing in the people, capabilities and organizational structure necessary to capitalize on significant opportunities across its markets while continuing to deliver exceptional products and service to healthcare providers and patients worldwide.
About Aspen Medical Products
Founded in 1994, Aspen Medical Products, LLC is the industry leader in the development and manufacturing of spinal orthopedics and pain therapy solutions. Designed to restore function and alleviate pain, Aspen’s products address a variety of patient needs across the continuum of care to help them resume activities of daily living. Headquartered in Irvine, California, Aspen has local sales representation throughout the U.S. and internationally. www.aspenmp.com
About Cortec Group
In 2019, Aspen Medical Products was recapitalized by an affiliate of Cortec Group, a New York-based private equity investment firm. Cortec partners with management teams to build market-leading middle-market companies across specialty healthcare, consumer, distribution, specialty services and specialty products sectors. Through its collaborative investment approach, Cortec helps companies accelerate growth, strengthen operations and create long-term value.
SOURCE Aspen Medical Products
Author
TH
TJ Halvorson
The De Angelis Group | Orthopedics This Week | MSK Innovations
Why This Matters
Two Perspectives
MBA Lens: Economic and industry impact
Aspen Medical Products has strategically separated its CEO and President roles to bolster continued growth, market expansion, and long-term value creation. This move aims to optimize executive focus, with the CEO concentrating on high-level strategic initiatives and the new President overseeing day-to-day operations. This leadership restructuring positions Aspen to capitalize on significant market opportunities and strengthen its competitive stance in spine solutions.
- CEO Jim Cloar will now prioritize strategic initiatives, mergers and acquisitions, innovation, and long-term expansion opportunities.
- President Steve Paul, with extensive commercial success in orthotics and medical devices, will manage daily operations and drive commercial performance.
PhD Lens: Clinical and outcomes impact
Aspen Medical Products, an industry leader in spine solutions, has enhanced its executive leadership to support ongoing development in pain and mobility management. Their products are designed to restore function and alleviate pain, addressing diverse patient needs. This organizational strengthening aims to accelerate strategic goals and continue delivering innovative solutions in spinal orthopedics, maintaining their commitment to healthcare providers and patients.
- Aspen specializes in the development and manufacturing of spinal orthopedics and pain therapy solutions.
- Products are designed to restore function and alleviate pain, addressing various patient needs across the continuum of care.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.